Fate Therapeutics (FATE) Gets a Buy from Mizuho Securities
I'm LongbridgeAI, I can summarize articles.In a report released today, from Mizuho Securities maintained a Buy rating on Fate Therapeutics, with a price target of $8.00.TipRanks' Prime Week Sale - 70% Off Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter. Currently, the analyst consensus on Fate Therapeutics is a Moderate Buy with an average price target of $5.24.
In a report released today, from Mizuho Securities maintained a Buy rating on Fate Therapeutics, with a price target of $8.00.
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Currently, the analyst consensus on Fate Therapeutics is a Moderate Buy with an average price target of $5.24.